Kardatuxan

Rivaroxaban, the active ingredient in Kardatuxan, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is indicated for the prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism.

GNH USA supplies Kardatuxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across extensive global jurisdictions.

Kardatuxan, a direct factor Xa inhibitor, is used in several anticoagulation pathways. - Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute clot formation and facilitates resolution. - Pulmonary embolism (PE): treats acute embolic events and improves pulmonary circulation. - Recurrent DVT/PE prevention: lowers incidence of repeat thrombotic episodes after initial treatment.

Rivaroxaban may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bruising or minor bleeding: superficial skin or mucosal hemorrhage. - Nosebleeds: intermittent epistaxis. - Headache: mild to moderate intensity. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal, intracranial or fatal hemorrhage. - Spinal or epidural hematoma: risk with neuraxial procedures. - Allergic reactions: rash, angioedema or anaphylaxis.

Before initiating Kardatuxan, clinicians should consider several safety measures. - Assess renal function: adjust dose in patients with impaired clearance. - Monitor for bleeding: watch for signs of hemorrhage during therapy. - Review concomitant antiplatelet use: evaluate additive bleeding risk. - Adjust in hepatic impairment: use caution in moderate liver disease. - Avoid in active major bleeding: discontinue if uncontrolled bleeding occurs. - Store at room temperature: keep in original container, protect from moisture.

Rivaroxaban interacts with several drug classes that may alter its anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, heparin): additive anticoagulation increases bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): markedly raise plasma levels. - Strong P‑glycoprotein inhibitors (e.g., verapamil, dronedarone): elevate exposure and bleeding potential.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): increase bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: heighten risk of mucosal bleeding.